Prolonged-release melatonin for insomnia – an open-label long-term study of efficacy, safety, and withdrawal

BACKGROUND: Prolonged-release melatonin (PRM) 2 mg is indicated for insomnia in patients aged 55 years and older. A recent double-blind placebo-controlled study demonstrated 6-month efficacy and safety of PRM in insomnia patients aged 18–80 and lack of withdrawal and rebound symptoms upon discontinu...

Descripción completa

Detalles Bibliográficos
Autores principales: Lemoine, Patrick, Garfinkel, Doron, Laudon, Moshe, Nir, Tali, Zisapel, Nava
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3150476/
https://www.ncbi.nlm.nih.gov/pubmed/21845053
http://dx.doi.org/10.2147/TCRM.S23036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3150476/
https://www.ncbi.nlm.nih.gov/pubmed/21845053
http://dx.doi.org/10.2147/TCRM.S23036

Ejemplares similares